Endoscopically placed stents: a useful alternative for the management of refractory benign cervical esophageal stenosis

• Main Authors: Óscar Nogales, Ana Clemente, Aránzazu Caballero-Marcos, Javier García-Lledó, Leticia Pérez-Carazo, Beatriz Merino, María López-Ibáñez, M. Dolores Pérez-Valderas, Rafael Bañares, Cecilia González-Asanza
• Format: Article
• Language: English
• Published: Aran Ediciones
• Series: Revista Espanola de Enfermedades Digestivas
• Subjects: Esophageal stents; Benign esophageal strictures; Cervical esophagus
• Online Access: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017000700006&lng=en&tlng=en

Introduction: Benign esophageal strictures are relatively frequent and can severely affect the quality of life of a patient. Stenting has been proposed for the treatment of refractory cases. Lesions affecting the cervical esophagus are more difficult to treat, and the placement of stents in this location has traditionally been restricted due to potential adverse events. The aim of this study was to describe the efficacy and safety of endoscopic stenting in the management of refractory benign cervical esophageal strictures (RBCES) in a single-center cohort study. Methods: We analyzed 12 patients with RBCES (Kochman's criteria) and severe dysphagia. We recorded previous endoscopic treatments, stricture characteristics and demographic data. The two types of stents used were fully covered self-expandable metallic stents (FCSEMS) and uncovered biodegradable stents (BDS). FCSEMS were removed eight weeks after placement, and BDS were followed-up until degradation. We assessed technical and clinical success, rate of stricture recurrence and adverse events. Results: The mean age of participants was 64 years (range 30-85). A total of 23 stents (13 FCSEMS and 10 BDS) were placed in 12 patients (median 1.92, range 1-4). The technical success rate was 96% (22/23 stents). Eight patients (66.6%) maintained adequate oral intake at the end of follow-up (median 33.3 months, range 3-84 months). Migration was recorded in 7/23 stents (30.4%) and epithelial hyperplasia in 4/23 stents (17.4%). No severe adverse events were noted. All patients complained of minor cervical pain after placement that was well controlled with mild analgesia. Conclusions: Endoscopic stent therapy seems to be effective and safe in the management of RBCES.